Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quaker Chemical (KWR) Asset Writedowns and Impairment (2020 - 2025)

Quaker Chemical (KWR) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with $88.8 million as the latest value for Q2 2025.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $88.8 million in Q2 2025 year-over-year; TTM through Dec 2025 was $88.8 million, a N/A change, with the full-year FY2025 number at $88.8 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $88.8 million for Q2 2025 at Quaker Chemical, up from -$93.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $93.0 million in Q4 2022 to a low of -$93.0 million in Q2 2023.
  • A 4-year average of $44.0 million and a median of $88.8 million in 2025 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 0.0% in 2021; the steepest drop was 0.0% in 2021.
  • Quaker Chemical's Asset Writedowns and Impairment stood at $38.0 million in 2021, then surged by 144.74% to $93.0 million in 2022, then crashed by 200.0% to -$93.0 million in 2023, then surged by 195.48% to $88.8 million in 2025.
  • Per Business Quant, the three most recent readings for KWR's Asset Writedowns and Impairment are $88.8 million (Q2 2025), -$93.0 million (Q2 2023), and $93.0 million (Q1 2023).